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Abstract: Pediatric high grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPGs), are aggressive
tumors with a dismal outcome. Radiotherapy (RT) is part of the standard of care of these tumors; however,
radiotherapy only leads to a transient clinical improvement. Delta-24-RGD is a genetically engineered tumor-
selective adenovirus that has shown safety and clinical efficacy in adults with recurrent gliomas. In this work, we
evaluated the feasibility, safety and therapeutic efficacy of Delta-24-RGD in combination with radiotherapy in
pHGGs and DIPGs models. Our results showed that the combination of Delta-24-RGD with radiotherapy was
feasible and resulted in a synergistic anti-glioma effect in vitro and in vivo in pHGG and DIPG models. Interestingly,
Delta-24-RGD treatment led to the downregulation of relevant DNA damage repair proteins, further sensitizing
tumors cells to the effect of radiotherapy. Additionally, Delta-24-RGD/radiotherapy treatment significantly increased
the trafficking of immune cells (CD3, CD4+ and CD8+) to the tumor niche compared with single treatments.
In summary, administration of the Delta-24-RGD/radiotherapy combination to pHGG and DIPG models is safe and
significantly increases the overall survival of mice bearing these tumors. Our data offer a rationale for the
combination Delta-24-RGD/radiotherapy as a therapeutic option for children with these tumors.
Significance: Delta-24-RGD/radiotherapy administration is safe and significantly increases the survival of
treated mice. These positive data underscore the urge to translate this approach to the clinical treatment of
children with pHGG and DIPGs.
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Introduction
Pediatric high grade gliomas (pHGG) and diffuse intrinsic
pontine gliomas (DIPGs) are malignant tumors present with
an aggressive behavior [7]. Integrated molecular profiling
has contributed to renew the classification of these tumors
by considering the mutations encoding histone H3 variants
that determine localization, age of presentation, clinical
outcome or even radiological features [18, 25, 30, 41].
The current standard therapy for pHGG consists of
maximal surgical resection followed by temozolomide/
radiotherapy (RT) [35]. In the case of DIPGs, effective
therapeutic options are limited, and the standard of care is
RT. RT offers a temporal decrease of clinical symptoms
and an increase in the overall survival; however, it is not
curative [12] . Despite combined efforts to develop new
therapies for these aggressive tumors, over the last decade,
the overall survival is 15months for pHGG patients and
approximately 9 to 11months for DIPGs [16].
RT induces DNA damage [24], resulting in the triggering
of either cell death programs or cell survival mechanisms,
such as apoptosis, necrosis or autophagy, among others
[6]. Radiation-induced cell responses mediated by DNA
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damage cause tumor antigens release, generation of
ROS species or production of cytokines, which awake
the immune system [31]. Recent studies demonstrate
that RT also induces an immunogenic cell death that
promotes the recruitment of different immune popula-
tions to the tumor bed. In some instances, RT triggers
an abscopal effect which results in an effective immun-
ity against the tumor [9]. However, the RT mediated
abscopal effect is seen in few patients and many times
is hampered by the tolerance and an immunosuppres-
sive tumor microenvironment [28].
In this study, we evaluated whether the combination
of the oncolytic adenovirus, Delta-24-RGD (DNX-2401)
[36], genetically engineered to destroy cancer cells, in
combination with RT would result in a superior anti-
tumor effect in pHGG and DIPGs when compared to
either agent alone. Delta-24-RGD administration has
been demonstrated to be safe and therapeutically
effective in a subset of adult patients with recurrent
glioblastoma [22]. Moreover, clinical and preclinical
studies with Delta-24-RGD have shown that part of
the antitumor effect is due to the capacity of the virus
to boost or awake the patient’s immune system [15].
We have previously shown that administration of
Delta-24-RGD alone resulted in a robust antitumor
effect in vitro and in vivo in pHGGs and DIPGs models
(Martinez-Velez et al., 2019, nature communication, in
press). Moreover, our group and others have shown that
adenoviral infection inhibits the cellular DNA repair ma-
chinery to increase its replication potency [34]. We hy-
pothesized that DNA repair inhibition by viral
administration could sensitize tumor cells to irradiation,
increasing the therapeutic effect [29]. Furthermore, RT/
Delta-24-RGD administration will increase the release of
tumor antigens overcoming the “cold” status of pHGG
and DIPG tumors and triggering a stronger immune re-
sponse that could translate into a synergistic antitumor ef-
fect and an increase of the overall survival in these
patients.
Material and methods
Cell lines and culture conditions
Pediatric glioma CHLA-03-AA (H3 WT) was obtained
from the America Type Culture Collection (ATCC,
Manassas, VA). PBT-24 pediatric glioma cell line was
developed from a biopsy (H3 WT) obtained at the
University Clinic of Navarra from a 13-year-old boy.
Tumor samples were obtained with a signed-informed
consent. Tumors were cut into smaller pieces, and cells
were dissociated enzymatically. Cell obtained from dis-
sociation were cultured with RPMI medium supple-
mented with 10% FBS and 1% antibiotic. Cell lines
obtained from ATCC or Chilren Oncology Group (COG)
were cultured following manufacturer specifications. The
DIPG cell line TP54 (H3.3K27M) was kindly provided by
Drs. Marie-Pierre Junier and Hervé Cheneiwess (INSERM
Institute, Paris, France), and the SU-DIPG IV (H3.1K27M)
cell line was a kind gift from Michelle Monje (Stanford
University, CA). The DIPG cell line was maintained as
neurospheres cultured in a specialized serum-free basal
medium complemented with a human neural stem cell
proliferation supplement (NeuroCult™ NS-A Proliferation
Kit, #05751, STEMCELL Technologies) supplemented
with basic fibroblast growth factor and epidermal
growth factor (20 ng/mL Sigma-Aldrich, St Louis, MO).
All cells were maintained in a humidified atmosphere
containing 5% CO2 at 37 °C. All of the cell lines were
tested and authenticated at the CIMA Genomic Core
Facility (Pamplona, Spain) using short tandem repeats
DNA profiling.
The murine DIPG cell lines NP53 and XFM were pro-
vided by Dr. Becher (Northwestern University, Chicago,
IL). Cell lines were generated from DIPG tumors arisen
in genetically modified mice. The NP53 cell line was
generated from tumors that arose in a DIPG mouse
model induced by PDGF-B signaling, p53 loss, and
ectopic H3.3-K27M [10]. The XFM cell line was generated
from tumors developed in a mouse model driven by
PDGF-B signaling and Ink4a and ARF loss [3].
Adenovirus construction and infection
Construction of Delta-24-RGD and viral infection have
been previously described [26, 40].
Viral replication assays
pHGG and DIPG cells were seeded at a density of 2 × 105
cells/well in 6-well plates and infected with 10 MOI of
Delta-24-RGD, and 4 h after infection, these cells were
irradiated with three different doses (3, 6 and 12Gy).
Three days later, cells were collected, and the final amount
of virus was determined by means of a method based on
anti-hexon staining in HEK293 cells [4].
Cell viability assay
Cells were seeded at a density of 2 × 105 cells per well in
6-well plates, and the next day, cells were infected with
10 MOIs of Delta-24-RGD. In addition, cells were irradi-
ated at doses of 3, 6 and 12 Gy. Cell viability was
assessed 5 days later using trypan blue. Dose–response
curves were analyzed using GraphPad software. Quanti-
fication of viability was measured in triplicate, and each
experiment was performed three times. After fitting the
combined dose-response curve from a single represen-
tative experiment to a Chou–Talalay line, Chou–Talalay
combination indices (CIs) were calculated with Calcusyn
software (Biosoft, Cambridge, UK). Levels of interaction
are defined as follows: CI > 1.1 indicates antagonism,
CI between 0.9 and 1.1 indicates additive effect, and
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CI < 0.9 indicates synergy [5]. A mean CI was calculated
from data points with the fraction affected (FA) > 0.5. The
FA range used to calculate the average CI values in the
combination experiments did not include CI values of FA
< 0.5, which was not considered a relevant growth inhi-
bition because one aims to achieve the maximal effect of
the combination tested on cancer cells.
Immunoblotting
For immunoblotting assays, samples were subjected to
SDS-Tris-glycine gel electrophoresis. Membranes were
incubated with the following antibodies: E1A, (Santa Cruz
Biotechnology, Santa Cruz, CA), fiber (NeoMarkers,
Fremont, CA), Mre-11, Rad 50, Rad 51, pH2Ax,
MPG (Cell Signaling, Danvers, MA) and GRB-2
(Sigma-Aldrich). The membranes were developed accord-
ing to Amersham’s enhanced chemiluminescence protocol.
Animal studies
Ethical approval for animal studies was granted by the
Animal Ethical Committee of the University of Navarra
(CEEA; Comité Etico de Experimentación Animal under
the protocol number CEEA/069–13). All animal studies
were performed in the veterinary facilities of the Center
for Applied Medical Research in accordance with insti-
tutional, regional, and national laws and ethical guide-
lines for experimental animal care. For the orthotopic
supratentorial model, CHLA-03-AA cells (5 × 105) were
engrafted by injection into the caudate nucleus of athy-
mic mice. TP54 cells (5 × 105) developed DIPG tumors
by injection of those cells into the pons of athymic mice
in both models, we have utilized a guide-screw system.
(Taconic Farms, Inc.). NP53 cells (5 × 105) were im-
planted in transgenic mice, kindly provided by Dr. Oren
Becher. Cells were administered in 3–4 μl of PBS.
Animals were randomized to 2 or 4 groups (controls
without treatment, Delta-24-RGD, irradiated, and com-
bination of radiation and Delta-24-RGD). Delta-24-RGD
(107 pfu/animal) was administered intracranially once in
3–4 μl 3 days after cell implantation. A week later, brain
tumors were irradiated (4 Gy) using the bolt as a guide
to administer irradiation to that area.
Tumor establishment procedure
Under aseptic conditions and with all materials sterilized
according to standard techniques, mice of 4 weeks of
age were anesthetized by intraperitoneal injection with
ketamine and xilacyne solution. The animal heads were
supported by a couple of rolled gauzes so that when the
screw was inserted, pressure applied over neck and head
structures was better tolerated by the animal.
We prepared mice head skin with povidone iodine
solution prior to make a 5 mm-long lineal skin incision
with 23-size scalpel and expose skull sutures. We first
made a small mark according to the coordinates with a
small 15-gauge needle which was subsequently widened
with a hand-controlled twist drill which penetrates the
skull. Next, we introduced the screw with its specific
screwdriver by applying slight pressure throughout the
previous twist hole. The coordinates for generation of
DIPG tumors are 1.0 mm right to lambda and just pos-
terior (0.8 mm) to lambdoid suture, while coordinates
for pHGG tumors are from bregma (intersection be-
tween coronal and sagittal suture) 1 mm anterior and
2.5 mm to the right. Thereafter the needle of Hamilton
syringe is slowly introduced into the hole by applying gen-
tle pressure until the sleeve/cuff from the syringe reaches
the screw surface. The desired depth to reach brainstem is
6.5 mm and depth for hemispheric tumors (pHGG) is
3.5 mm. Cell suspension was carefully injected using an
infusion pump (Harvard Apparatus) over 20 min.
Comet assay
Cell lines were irradiated with ascending doses (ranging
from 3 to 12 Gy) and infected with Delta-24-RGD at 10
MOIs; 72 h later, cells were recollected. Cells were pre-
pared following the manufacturer protocol provided by
CometAssay® kit (Trevigen, Inc., Gaithersburg, MD).
Immunohistochemical analysis
The paraffin-embedded sections of the mice brains were
immunostained for antibodies specific for adenoviral
mouse-hexon (Chemicon International, Inc., Temecula,
CA), adenovirus rabbit-E1A, (Santa Cruz Biotechnology,
Santa Cruz, CA), pH2Ax (Cell Signaling, Danvers, MA),
CD3 (NeoMarkers, Fremont, CA), CD4 (Abcam, Cambridge,
MA) CD8a (Cell Signaling, Danvers, MA), FoxP3 (eBio-
sciences, Thermo Fisher, Waltham, MA) and vimentin clone
V9 (IS30, Dako Denmark A/S, Glostrup, Denmark),
following manufacturer procedures. For immunohisto-
chemical staining, Vectastain ABC kits (Vector Labo-
ratories Inc., Burlingame, CA) were used according the
manufacturer’s instructions.
Statistical analysis
For the in vitro experiments, data are expressed as the
mean ± SD, and comparisons were evaluated by the
two-tailed Student’s t test or ANOVA. The effect of
Delta-24-RGD and RT, alone or in combination, and
pHGG and DIPG xenografts was assessed by plotting
survival curves according to the Kaplan-Meier method.
Survival in different treatment groups was compared
using the log-rank test. The program GraphPad Prism
5 (Statistical Software for Sciences) was used for the
statistical analysis.
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Results
Combination of Delta-24-RGD with RT exerts a synergistic
antitumor effect in pHGG and DIPG in vitro and in vivo
First, to evaluate whether irradiation would interfere
with viral replication, we infected pHGG and DIPG cells
with Delta-24-RGD (10 MOIs) followed by increasing
doses of RT: 3 , 6 and 12 Gy. After the combined treat-
ment, we observed a robust expression of the viral late
protein fiber regardless of the RT dosage used (Fig. 1a
and Additional file 1: Figure S1A). This result suggested
that RT does not interfere with the viral cycle. To sup-
port this notion, we quantified the viral progeny present
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Fig. 1 Radiotherapy is amenable to combine with Delta-24- in vitro and in vivo in the DIPG and pHGG models. a Evaluation by western blotting
of the expression of viral proteins after Delta-24-RGD (10 MOIs) infection and subsequent irradiation (3 , 6 and 12 Gy) in TP54 and CHLA-03-AA. b
Quantification of Delta-24-RGD replication in the indicated cell lines irradiated with different Gy doses. The viral titers were determined 3 days
after infection at an MOI of 10 by an anti-hexon staining-based method in 293 cells and expressed as plaque-forming units (pfu) per milliliter.
Data are shown as the mean ± SD of three independent experiments and analyzed with two-tailed Student-t test, not significant differences were
found. c Cell viability analyses of irradiated cells at the indicated Gy doses alone (Mock; control with a mock infection) or in combination with
Delta-24-RGD. Cell viability was assessed 5 days after irradiation and viral infection using an automatic cell counter that measures cell viability (life,
death and total cells) with the standard trypan blue reaction. Data are shown as the percentage (the mean ± SD) of viability after treatments and
relative to control cells (neither infected nor irradiated). Statistical significance were calculated using two-tailed Student-t test, ns, not significative;
*, P < 0.05; **, P < 0.01; ***, P < 0.001. d Kaplan-Meier survival curves of nude mice bearing orthotopic DIPGs (TP54) or pHGG (CHLA-03-AA) tumors
that were treated with either Delta-24-RGD (107 pfu), irradiation (4 Gys) or combined treatment. Log-rank test were used for statistical analyses
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in cells after irradiation with increasing Gys. We found
that Delta-24-RGD replication was not hindered by any
of the irradiation doses evaluated (Fig. 1b and Additional
file 1: Figure S1B). These data confirmed the feasibility
of combining RT with the Delta-24-RGD virus. Next, we
evaluated the anticancer effect of this combination in a
panel of the pHGG and DIPG cell lines. Our results
showed that RT alone, at the highest dose used of 12 Gy,
induced only a modest increment of cell death, 30–40%,
in the pHGG (CHLA-03-AA and PBT-24) and DIPG cell
lines (TP54 and SU-DIPG IV) (Fig. 1c, Additional file 1:
Figure S1C and Table 1). The TP54 DIPG cell line was
more susceptible to RT, with a 70% cell death at the
12 Gy dose (Fig. 1c and Additional file 1: Figure S2A).
Combination of RT with Delta-24-RGD induced an
increase in the cytotoxicity with a viability decrease of
approximately 20–40% when compared with the single
treatment (Fig. 1c and Table 1) (P < 0.001). Evaluation of
the combinatory index (CI) showed that RT plus
Delta-24-RGD had a synergistic antiglioma effect in all
doses tested in the PBT-24 and TP54 cell line. In the
CHLA-03-AA and SU-DIPG IV cell lines, combination
treatment presented a synergistic effect (CI = 0.17–0.76)
at the highest irradiation doses (6 and 12 Gy); mean-
while, at the lowest irradiation dose (3 Gy), an additive
effect with Delta-24-RGD resulted (CI = 0.9–1.1) (Table 1).
Next, we wanted to assess whether in vivo combi-
nation of Delta-24-RGD with RT would show the same
synergistic effect that we observed in vitro in the pHGG
and DIPG cell lines to determine the optimal dose to the
mice pons. The results showed that any of tested doses
evaluated presented toxicity (Additional file 1: Table S1).
Next, we evaluated which dose accurately reproduced
the clinical behavior presented in patients. We estab-
lished that 4 Gy irradiation produces a transient delay in
tumor growth similar to that in patients but with no
curative effect.
We used the CHLA-03-AA (pHGG) and TP54 (DIPG)
cell lines to assess the in vivo combination efficacy. A
single dose (107 pfu) of Delta-24-RGD was injected
intratumorally at day 3 followed by RT (4 Gy) at day 4.
Animals were monitored during the experiment, and
they were sacrificed when they presented signals of
physical deterioration derived from high tumor bur-
den presence.
Survival analyses showed that RT increased the median
survival of mice in 6 days in the TP54 model (P = 0.39)
(Fig. 1d and Table 2) and in 7 days in the CHLA-03-AA
model (P = 0.003) (Fig. 1d). Combination of virus/RT
compared with single RT significantly increased the
survival in both models (P = 0.009 and P < 0.006, res-
pectively). Importantly, combination treatment of mice
bearing the CHLA-03-AA resulted in 3 long-term sur-
vivors free of disease (N = 3) (P < 0.0001). Mice bearing
the TP54 orthotopic DIPG model also benefitted from
the RT/virus combination with a significant increase
of 20 days (P = 0.01) in the overall survival.
These data suggest that combination of virus and RT
could be synergistic not only in vitro but also impor-
tantly in vivo, allowing a reduction in the RT doses to
achieve the same effect.
In summary, the combination of irradiation and
Delta-24-RGD is a feasible therapeutic strategy that
increases the antitumor effect in vitro and increases
the overall survival when compared with single treat-
ment (RT or Delta-24-RGD) administration in pHGG
and DIPG models.
Delta-24-RGD inhibits important proteins involved in the
DNA damage cellular response
RT induces DNA damage in cancer cells, and hence, if
left unrepaired, the cells die [24]. Of importance, our
group and others [14, 17, 20, 34] have shown that
adenoviral proteins are able to inhibit different
Table 1 Median-effect doses (%viability) of Delta-24-RGD alone
or combined with different doses of radiotherapy in the pHGG
and DIPG cell lines. The value is the viability percentage ± SD of
cells irradiated with different doses or cells irradiated with
different doses and infected with a single viral dose. The
interaction between RT and Delta-24-RGD in pHGG and DIPG
cell lines was measured by combination index (CI) values. The
interaction was measured according to the combination index
values. Combination index values > 1.3 indicated antagonism,
values between 1.1 and 1.3 indicated moderate antagonism,
values between 0.9 and 1.1 indicated additivity, values between
0.8 and 0.9 indicated slight synergy, values between 0.6 and 0.8
indicated moderate synergy, values between 0.4 and 0.6
indicated synergy, and values < 0.4 indicated strong synergy.
Each combination was studied in three independent
experiments, the differences of which were not statistically
significant. The results of single experiments are shown
Cell lines IR (Gy) Mock +Delta-24-RGD CI
pHGG CHLA-03-AA 3 94.76 ± 7.07 54.77 ± 7.07 1.10
6 86.26 ± 5.2 47.17 ± 7.74 0.76
12 53.10 ± 5.23 35.33 ± 5.03 0.41
PBT-24 3 90.1 ± 3.03 38.2 ± 3.13 0.45
6 81.4 ± 6.74 29.9 ± 7.22 0.36
12 73.9 ± 4.46 19.9 ± 8.66 0.19
DIPG TP54 3 93.5 ± 9.19 16.0 ± 7.07 0.33
6 58.5 ± 7.7 10.2 ± 0.35 0.18
12 22.5 ± 0.7 6.5 ± 0.7 0.17
SU-DIPG IV 3 88.0 ± 1 38.2 ± 3.13 0.97
6 82.0 ± 6.74 29.9 ± 7.22 0.48
12 73.9 ± 4.46 19.9 ± 8.66 0.19
IR Irradiated dosage, CI Combinatory index, Mock non infected cells
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components of the cell DNA damage repair machinery
to facilitate their replication in the host. Interestingly,
viral inhibition of the DNA damage repair protein could
contribute to sensitizing tumor cells to agents that cause
DNA damage. Therefore, we evaluated the expression of
several proteins involved in DNA damage to understand
whether the inhibition of the DNA damage repair
machinery could be underlying the synergistic effect
of treatment combination.
We observed that Delta-24-RGD infection resulted in
the inhibition of cellular machinery, involving Rad50
and Mre11 proteins; both proteins are part of the MRN
complex [21, 33] which is involved in the repair of
double strand breaks (DSB) (Fig. 2a and Additional file
1: Figure S3A); Rad 51 is also inhibited, a protein with a
major role in the homologous recombination repair
(HRR [13, 27]). MPG protein is able to initiate the base
excision repair (BER) mechanism that repairs alkylating
bases [1, 39, 42] (Fig. 2a and Additional file 1: Figure S3A).
The expression of these proteins is altered in refractory
cancer cells as machinery of resistance to chemotherapy or
radiotherapy [2, 44] .Interestingly, pH2Ax protein is also
inhibited when tumor cells are infected, even after higher
doses of irradiation (Fig. 2a and Additional file 1:
Figure S3A). Phosphorylation of H2Ax marks a double
strand break; therefore, pH2Ax inhibition could represent
an advantage for the therapy. DNA repair machinery of
infected tumor cells is unable to detect DNA damage
caused by RT (Fig. 2b, c and Additional file 1: Figure S3B
and S3C) and not repair it, increasing DNA damage that
prompts in cell death.
Histological analyses showed that Delta-24-RGD com-
bined with RT is able to replicate in pHGG and DIPG in
vivo. Positive immuno-staining against viral proteins are
found in tumors after irradiation in vivo (Fig. 2d).
Our results suggest that the synergistic antitumor
effect that we observed in combination adenovirus/RT
could be explained, at least in part, by the inhibition that
the adenovirus exerts on the cell DNA damage repair
machinery and the subsequent increase in DNA damage.
Delta-24-RGD combined with RT enhanced the antitumor
effect in murine DIPG cell lines
In addition, we wanted to elucidate how the immune
response contributed to the synergistic effect of this
combination.
To this end, we evaluated the combination of Delta-24-
RGD plus RT in the XFM and NP53 murine DIPG cell
lines [3, 10]. Previously, we showed that these cell lines
were semipermissive to Delta-24-RGD (Martinez-Velez et
al., 2019 in review); therefore, these cell lines constitute a
good model to analyze immune response to the viral in-
fection. We observed that fiber protein, a late protein
that is part of the adenoviral capsid, is robustly expressed
after the highest dose of RT (Fig. 3a). At the functional
level, we did not observe variations between viral titers
obtained in non-irradiated versus irradiated infected cells
(Fig. 3b). Importantly, treatment of these cell lines with
RT alone was not capable of decreasing the viability more
than 50% at the highest dose used (12 Gy), given that
NP53 is the most sensitive cell line. The addition of
Delta-24-RGD resulted in a significant decrease in cell
viability, between 40 and 70%, compared with the single
treatment (Fig. 3c).
Therefore, we can conclude that the combination of
Delta-24-RGD/RT increases the cytotoxicity of a single
treatment in DIPG murine cell lines in vitro.
Delta-24-RGD /RT treatment triggers a potent immune
response in a murine DIPG model
Since it has been described that anti-tumor immune
effect mediated by local RT is more prominent after a
previous immune activation [8, 32] we analyzed whether
combined Delta-24-RGD/RT treatment resulted in a
heightened immune response.
Table 2 Median survival and log-rank test P-value of different treated groups in a DIPG and pHGG model. P value 1 shows the P
value of the comparison of each group with the PBS group, P value 2 compares each group with the Delta-24-RGD-treated group
and P value 3 compares radiotherapy with the combination group
Survival (Days) P value [7] P value [18] P value [30]
DIPG TP54 Control 83
Delta-24-RGD 95 0,04
RT 89 0,39 0,2
RT + Delta-24-RGD 106 0,005 0,02 0,009
pHGG CHLA-03-AA Control 42
Delta-24-RGD 48 0,01
RT 49 0,003 0,2
RT + Delta-24-RGD 62 < 0,0001 0,1 0,006
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Mice bearing NP53 DIPG tumors were administered a
single injection of Delta-24-RGD followed 1 day later by
RT. Histopathology examination of mice tumors treated
with the combination showed an increase in tumor
immune CD3 infiltration when compared with the single
treatment. Moreover, we observed perivascular cuffing
in mice brain treated with RT/Delta-24-RGD, indicating
an immune cell recruitment triggered by the com-
bination, mainly CD4+ and CD8+ (Figs. 4a, b, c and
Additional file 1: Figure S4).
Quantification of CD3, CD4 and CD8 positive cells
(Figs. 3d, e and f) showed a modest increase in lympho-
cyte infiltration in irradiated tumors (2.02, 3.06 and





Fig. 2 Delta-24-RGD downregulation of the cellular DNA damage repair machinery in the DIPG and pHGG cell lines. a Expression analyses by
western blotting of the relevant proteins involved in the DNA damage response to RT in the DIPG and pHGG cell lines after the indicated
treatments. The proteins levels were evaluated 72 h after cells were treated. b Evaluation of DNA damage upon treatment with Delta-24-RGD
and/or RT by the comet assay. TP54 cells were administered the indicated treatments, and 72 h later, the induction of comets was assessed.
Representative photomicrographs of comets shown by the cells after the indicated treatment (magnification, × 200). c Quantification of positive
cells showing comets after the indicated treatment. Data are shown as the percentage of comet tails found per treatment percentage (n = 500
cells per treatment); bars represent means ± SD. All experiments were performed in triplicate and analyzed using two-way ANOVA and corrected
for multiple comparision with Bonferroni posttest; **, P < 0.01 and ***, P < 0.001. d Hexon immune-staining representative images (scale bar
=100um) after the indicated treatments. The above images images show differences in hexon protein expression in CHLA-03-AA tumors while
below images show hexon staining in TP54 tumors
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tumors treated with Delta-24-RGD alone (2.46, 4.6 and
5.35-fold, respectively). Tumors treated with both agents
showed a significant increase in the recruitment of
immune populations (7.83, 6.2 and 8.89-fold) (CD3+,
CD4+ and CD8+) (P = 0.032, P = 0.318 and P = 0.065),
respectively. Evaluation of pro-inflammatory cytokines
expression levels, such as Granzyme B (P = 0.19) and
IFNg (P = 0.13), in addition to CD4 (P = 0.57) and CD8a
(P = 0.16) expression levels, presented an increased trend
in tumors treated with Delta-24-RGD and irradiation
compared with single treatments (Fig. 3g), indicating
that the combination stimulates the immune response in
DIPG tumors. All together, these results demonstrate
that combination of RT and Delta-24-RGD in vivo trig-
gers a potent immune response that increases the im-
mune recruitment at the tumor bed and the production
NP 53

















































Fig. 3 Combination of Delta-24-RGD/radiotherapy exerts a potent oncolytic effect in the NP53 and XFM murine DIPG cell lines. a Analyses of the
expression of viral late protein fiber in murine cell lines 42 h after the indicated treatments by western blotting. b Quantification of Delta-24-RGD
replication in the indicated cell lines. Viral titers were determined 3 days after infection with Delta-24-RGD (100 MOIs) and irradiation with either 3,
6 or 12 Gy. The viral titers were quantified using the anti-hexon staining-based method in 293 cells and expressed as plaque-forming units (pfu)
per milliliter. The data are shown as the mean ± SD of three independent experiments. c Cell viability analyses of the combination treatment in
DIPG murine cell lines. Cell viability was assessed 5 days after irradiation and/or viral infection using an automatic cell counter that measures cell
viability (life, death and total cells) with the standard trypan blue reaction. Data are shown as the percentage (mean ± SD) of viability
after irradiation at the indicated doses alone or also infected with Delta-24-RGD and analyzed with Two-tailed Student t-test
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of inflammatory cytokines that could mediate an antitu-
mor immune response.
Discussion
Previous works demonstrated that the oncolytic adeno-
virus Delta-24-RGD exerts a potent antitumor effect in
pHGG and DIPG preclinical models. pHGG and specif-
ically, DIPGs, are the most aggressive brain tumors with
dismal outcomes and ineffective therapeutic options
[38]. Clinical trials testing single agents as unique treat-
ments have resulted in limited efficacy. The standard
treatment for unresectable tumors is hypo fractionated
RT [11], which improves the quality of life of these
children transitorily, but in a few months, the tumors
will relapse. Therefore, the valuation of the thera-
peutic benefit of the Delta-24-RGD/RT combination is
extremely timely.
One of our findings was that the increase in cytotox-
icity of Delta-24-RGD/RT in vitro and in vivo in pHGG
and DIPG models could be mediated by the inhibition of
the cellular DNA repair mechanisms resulting in an
increase in DNA damage. Delta-24-RGD administration
has been described to inhibit proteins involved in DNA
repair to allow viral replication [29]. We observed the
inhibition of proteins that play a main role in double













Fig. 4 Administration of Delta-24-RGD in combination with radiotherapy heightens the immune infiltration in DIPG murine tumors. a Representative
images of immune infiltration, such as perivascular cuffing, after Delta-24-RGD/RT treatment. The mouse brain stained against CD3 (a), CD4 (b) and
CD8 (c). d Quantification of positive CD3+, e CD4+, and f CD8+ cell infiltration per mm2 of DIPG tumors. Graph showing the quantification of positive
cells infiltrating the brain 15 days after the indicated treatments per mm2 (PBS, RT, Delta-24-RGD and Delta-24-RGD/RT; n = 2–3). Comparisons were
analyzed with One-way ANOVA. g Quantification of Granzyme B, IFN gamma, CD8a and CD4 mRNA expression. The data shown represent mRNA
expression in tumors treated with Delta-24-RGD, RT, and Delta-24-RGD/RT normalized to the average of PBS-tumors mRNA expression (n = 2). Data
were analyzed with One-way ANOVA
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that are part of the MRN complex, in pediatric glioma
cells infected with Delta-24-RGD. The inhibition of the
host cellular DNA repair machinery is sustained after ir-
radiation, resulting in cellular machinery incapable of
repairing the DNA damage and thus sensitizing cells to
irradiation-induced cell death. Inhibition of Rad51 and
MPG has been described to sensitize glioma cells to
other agents [43], such as TMZ [2], a drug that is
commonly used to treat brain tumors, opening new
therapeutic combination options.
Recent evidence has shown that in addition to tumor
growth delay mediated by DNA damage-induced cell
death, RT also performs an immunostimulatory effect
that is triggered by the activation of immune cells or by
the modification of the tumor bed [8, 31]. The antitumor
systemic effect found after local irradiation is defined as
the abscopal effect and induces tumor recognition by
immune cells [19]. Delta-24-RGD has been shown to
unleash an immune response in a clinical trial phase I/II
performed in recurrent adult gliomas [22].
We observed that Delta-24-RGD/RT increased the
lymphocyte infiltration in DIPG tumors (including CD4
+ and CD8+ cells), and the mRNA evaluation showed
an increase in the expression of several cytokines. Viral
administration stimulates immune infiltration, which
that overcomes the immune “cold” status of these
tumors [23]. It has been hypothesized that RT fails to
develop an abscopal effect because of the active immuno-
suppression sustained by the tumor microenvironment.
The immune system boost induced by Delta-24-RGD
administration offers the immune activation that is ne-
cessary to stimulate the trafficking of immune specific
effector cells into the tumor niche that RT needs to trigger
the abscopal effect.
Therefore, Delta-24-RGD/RT administration could re-
present a promising therapeutic combination, considering
the awakening of the immune system, which could
increase the probability of developing a specific immune
response against tumor cells that would translate to an
effective antitumor effect.
Our results have supported the opening of a new
clinical trial phase I/II in our institution to evaluate
the safety and efficacy of Delta-24-RGD adminis-
tration followed by RT in patients with newly diagnosed
DIPG [37].
Conclusion
In conclusion, Delta-24-RGD alone or in combination
with RT is a promising therapy for DIPG and pHGG
patients, and additional studies to understand the
virus-induced immune response in patients could im-
prove immune-virotherapy approaches to fight against
these aggressive tumors.
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